Core Insights - Guardant Health reported a breakout year in 2025, with total revenue growth accelerating to 33% year-over-year, driven by innovation in its Smart Platform and strong commercial execution [2][5] - The company highlighted the success of its Shield product in the blood-based colorectal cancer screening market, with nearly 100,000 patients screened since FDA approval [2][5] - Guardant Health plans to launch multiple groundbreaking products in 2026 to sustain growth momentum in its Oncology business [2] Financial Performance - For Q4 2025, total revenue was approximately $280 million, an increase of 39% compared to Q4 2024 [5] - The company reported approximately 79,000 oncology tests in Q4 2025, a 38% increase year-over-year [5] - For the full year 2025, total revenue reached approximately $981 million, reflecting a 33% increase from 2024 [5] - The number of oncology tests conducted in 2025 was approximately 276,000, marking a 34% increase [5] - Shield screening tests totaled approximately 87,000 in 2025, up from 6,400 in the prior year [5] Cash Flow and Financial Position - Preliminary unaudited free cash flow was approximately negative $54 million for Q4 2025 and approximately negative $233 million for the full year 2025 [2] - As of December 31, 2025, the company had approximately $1.3 billion in cash, cash equivalents, restricted cash, and marketable debt securities [2]